MDT

90.2

+2.24%↑

VEEV

283.47

+1%↑

A

124.12

+2.54%↑

WBA

11.6

+0.43%↑

HQY

99.47

-1.71%↓

MDT

90.2

+2.24%↑

VEEV

283.47

+1%↑

A

124.12

+2.54%↑

WBA

11.6

+0.43%↑

HQY

99.47

-1.71%↓

MDT

90.2

+2.24%↑

VEEV

283.47

+1%↑

A

124.12

+2.54%↑

WBA

11.6

+0.43%↑

HQY

99.47

-1.71%↓

MDT

90.2

+2.24%↑

VEEV

283.47

+1%↑

A

124.12

+2.54%↑

WBA

11.6

+0.43%↑

HQY

99.47

-1.71%↓

MDT

90.2

+2.24%↑

VEEV

283.47

+1%↑

A

124.12

+2.54%↑

WBA

11.6

+0.43%↑

HQY

99.47

-1.71%↓

Search

Pulmatrix Inc

Open

6.32 0.8

Overview

Share price change

24h

Current

Min

6.15

Max

6.47

Key metrics

By Trading Economics

Income

178K

-1.8M

Profit margin

-60,266.667

Employees

2

EBITDA

144K

-1.8M

Market Stats

By TradingEconomics

Market Cap

1.5M

24M

Previous open

5.52

Previous close

6.32

Pulmatrix Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lip 2025, 15:46 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lip 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 20:26 UTC

Earnings

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lip 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lip 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lip 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lip 2025, 17:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lip 2025, 16:14 UTC

Acquisitions, Mergers, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lip 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lip 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lip 2025, 15:31 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250M Private Placement

9 lip 2025, 15:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lip 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lip 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lip 2025, 14:31 UTC

Acquisitions, Mergers, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lip 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 lip 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Comparison

Price change

Pulmatrix Inc Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.